# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Oren Livnat reiterates Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintains $57 price t...
Barclays analyst Balaji Prasad maintains Pacira BioSciences (NASDAQ:PCRX) with a Overweight and lowers the price target from...
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $45 to...
Pacira BioSciences (NASDAQ:PCRX) reported quarterly Adj earnings of $0.62 per share which met the analyst consensus estimate. T...